Switch theme
Sign up to access all valuation multiples
Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.
1981
n/a
Last FY Revenue $37.6M
Last FY EBITDA $34.8M
$588M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Shanghai Hile Bio-Tech achieved revenue of $37.6M and an EBITDA of $34.8M.
Shanghai Hile Bio-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai Hile Bio-Tech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $37.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $22.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 60% | XXX | XXX | XXX |
| EBITDA | XXX | $34.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 93% | XXX | XXX | XXX |
| EBIT | XXX | $4.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 11% | XXX | XXX | XXX |
| Net Profit | XXX | $23.8M | XXX | XXX | XXX |
| Net Margin | XXX | 63% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shanghai Hile Bio-Tech's stock price is CNY 7 (or $1).
Shanghai Hile Bio-Tech has current market cap of CNY 4.7B (or $652M), and EV of CNY 4.2B (or $588M).
See Shanghai Hile Bio-Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $588M | $652M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shanghai Hile Bio-Tech has market cap of $652M and EV of $588M.
Shanghai Hile Bio-Tech's trades at 15.6x EV/Revenue multiple, and 16.9x EV/EBITDA.
Equity research analysts estimate Shanghai Hile Bio-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai Hile Bio-Tech's P/E ratio is not available.
See valuation multiples for Shanghai Hile Bio-Tech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $652M | XXX | $652M | XXX | XXX | XXX |
| EV (current) | $588M | XXX | $588M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 16.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 143.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 27.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 111.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShanghai Hile Bio-Tech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Shanghai Hile Bio-Tech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shanghai Hile Bio-Tech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shanghai Hile Bio-Tech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 93% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai Hile Bio-Tech acquired XXX companies to date.
Last acquisition by Shanghai Hile Bio-Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Hile Bio-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shanghai Hile Bio-Tech founded? | Shanghai Hile Bio-Tech was founded in 1981. |
| Where is Shanghai Hile Bio-Tech headquartered? | Shanghai Hile Bio-Tech is headquartered in China. |
| Is Shanghai Hile Bio-Tech publicy listed? | Yes, Shanghai Hile Bio-Tech is a public company listed on SHG. |
| What is the stock symbol of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech trades under 603718 ticker. |
| When did Shanghai Hile Bio-Tech go public? | Shanghai Hile Bio-Tech went public in 2015. |
| Who are competitors of Shanghai Hile Bio-Tech? | Similar companies to Shanghai Hile Bio-Tech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Shanghai Hile Bio-Tech? | Shanghai Hile Bio-Tech's current market cap is $652M |
| Is Shanghai Hile Bio-Tech profitable? | Yes, Shanghai Hile Bio-Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
